Anti-tumor immunity and vitiligo: from immune-related adverse reactions to protection from cancer.
作者信息
Mazzetto Roberto, Sernicola Alvise, Miceli Paola, Tartaglia Jacopo, Ciolfi Christian, Alaibac Mauro
机构信息
Dermatology Unit, Department of Medicine (DIMED), University of Padua, Padova, 35121, Italy.
出版信息
Immunotherapy. 2024;16(13):841-843. doi: 10.1080/1750743X.2024.2377954. Epub 2024 Jul 26.
Abstract
摘要
相似文献
1
Anti-tumor immunity and vitiligo: from immune-related adverse reactions to protection from cancer.抗肿瘤免疫与白癜风：从免疫相关不良反应到癌症防护
Immunotherapy. 2024;16(13):841-843. doi: 10.1080/1750743X.2024.2377954. Epub 2024 Jul 26.
2
Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know.检查点抑制剂的皮肤不良事件：肿瘤学家应了解的内容。
Immunotherapy. 2016 Dec;8(12):1437-1446. doi: 10.2217/imt-2016-0074.
3
Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy.合并症对接受免疫治疗的老年癌症患者免疫相关不良事件和生存的影响。
Future Oncol. 2025 Jun;21(14):1787-1796. doi: 10.1080/14796694.2025.2502313. Epub 2025 May 27.
4
Kobner phenomena as a complication of immune therapy of neoplastic disease.同形反应作为肿瘤疾病免疫治疗的一种并发症。
Autoimmunity. 1991;10(2):165. doi: 10.3109/08916939109004820.
5
Incidence, stage and outcome of malignant melanoma, keratinocyte and other cancers in individuals with vitiligo or alopecia: intraindividual or familial risks?白癜风或斑秃患者中恶性黑色素瘤、角质形成细胞癌及其他癌症的发病率、分期和预后：个体内或家族性风险？
Br J Dermatol. 2025 Jun 20;193(1):66-73. doi: 10.1093/bjd/ljaf074.
6
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.用于经手术或根治性放疗治疗的Ⅰ至Ⅲ期非小细胞肺癌的免疫疗法（不包括检查点抑制剂）。
Cochrane Database Syst Rev. 2017 Dec 16;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub2.
7
The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy.免疫治疗中肿瘤免疫与自身免疫的平衡作用
Cancer Immunol Res. 2018 Dec;6(12):1445-1452. doi: 10.1158/2326-6066.CIR-18-0487.
8
[A Wolf in Sheep's Clothing - Manifestation and Diversity of Immune-Related Adverse Events in Cancer Immunotherapy].《披着羊皮的狼——癌症免疫治疗中免疫相关不良事件的表现与多样性》
Laeknabladid. 2025 Jul;111(7-08):318-324. doi: 10.17992/lbl.2025.0708.849.
9
New perspectives on the role of vitiligo in immune responses to melanoma.白癜风在黑色素瘤免疫反应中作用的新观点。
Oncotarget. 2011 Sep;2(9):684-94. doi: 10.18632/oncotarget.323.
10
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.从抗 PD-1 免疫疗法中解耦肝癌反应和不良反应的免疫轨迹。
J Hepatol. 2022 Sep;77(3):683-694. doi: 10.1016/j.jhep.2022.03.039. Epub 2022 Apr 15.
本文引用的文献
1
Reduced risk of skin cancer and internal malignancies in vitiligo patients: a retrospective population-based cohort study in Taiwan.白癜风患者皮肤癌和内脏恶性肿瘤风险降低：台湾基于人群的回顾性队列研究。
Sci Rep. 2021 Oct 12;11(1):20195. doi: 10.1038/s41598-021-99786-9.
2
Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators.基于易于获取的临床指标预测黑色素瘤患者免疫检查点阻断单药治疗反应
Front Oncol. 2021 May 27;11:659754. doi: 10.3389/fonc.2021.659754. eCollection 2021.
3
Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management.转移性黑色素瘤的免疫疗法：新毒性及其管理的新情况。
Melanoma Manag. 2019 Nov 8;6(4):MMT30. doi: 10.2217/mmt-2019-0005.
4
Assessment of telomerase activity in nonsegmental vitiligo tissue: a pilot study.非节段性白癜风组织中端粒酶活性的评估：一项初步研究。
Clin Exp Dermatol. 2019 Oct;44(7):747-752. doi: 10.1111/ced.13892. Epub 2019 Jan 31.
5
Cancer Risks in Vitiligo Patients: A Nationwide Population-Based Study in Taiwan.台湾地区白癜风患者的癌症发病风险：一项基于全国人口的研究。
Int J Environ Res Public Health. 2018 Aug 27;15(9):1847. doi: 10.3390/ijerph15091847.
6
Risk of skin cancer in people with vitiligo: a systematic review and meta-analysis.白癜风患者患皮肤癌的风险：一项系统评价和荟萃分析。
Br J Dermatol. 2018 Oct;179(4):971-972. doi: 10.1111/bjd.16703. Epub 2018 Jul 22.
7
Skin Cancer Risk (Nonmelanoma Skin Cancers/Melanoma) in Vitiligo Patients.白癜风患者的皮肤癌风险（非黑色素瘤皮肤癌/黑色素瘤）
Dermatol Clin. 2017 Apr;35(2):129-134. doi: 10.1016/j.det.2016.11.003.
8
Vitiligo and overt thyroid diseases: A nationwide population-based study in Korea.白癜风与显性甲状腺疾病：韩国全国范围内基于人群的研究。
J Am Acad Dermatol. 2017 May;76(5):871-878. doi: 10.1016/j.jaad.2016.12.034. Epub 2017 Feb 24.
9
Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.肿瘤坏死因子-α抑制可使进展期白癜风的病情稳定。
Br J Dermatol. 2015 Sep;173(3):641-50. doi: 10.1111/bjd.14016. Epub 2015 Aug 25.
10
Prediction of the Occurrence of Melanoma and Non-melanoma Skin Cancer in Patients with Vitiligo.白癜风患者黑色素瘤和非黑色素瘤皮肤癌发生情况的预测
Acta Derm Venereol. 2016 Jan;96(1):106-7. doi: 10.2340/00015555-2179.
Zotero 插件